Skip Navigation

Annals of Oncology 2005 16(8):1215; doi:10.1093/annonc/mdi297
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content

© 2005 European Society for Medical Oncology

In this issue

The first 10% of the full text of this article appears below.


   Anti-obesity drug orlistat inhibits Her-2/neu
 
Orlistat has recently been demonstrated to exhibit antitumor properties towards prostate cancer cells by virtue of its ability to block the lipogenic activity of fatty acid synthase (FAS). FAS is up-regulated in about 50% of breast cancers, is an indicator of poor prognosis, and it has been functionally associated with the Her-2/neu (erbB-2) oncogene.

In this issue, Menendez . . . [Full Text of this Article]


   Mucinous histology predicts reduced 5-FU responsiveness in advanced CRC
 

   Prognosis and treatment in elderly AML
 

   Antimicrobial prophylaxis in allogeneic bone marrow transplantation
 

   Quote